Chairman & Director
Howard Pien has worked in the pharmaceutical and biotechnology industries for over 30 years. In addition to Juno, he currently serves as a director on three boards. He is the Chairman of Indivior PLC, the spinoff of the pharmaceutical division from UK based consumer goods conglomerate Reckitt Benckiser. He is on the boards of Immunogen, Inc. and Sage Therapeutics, Inc. Previously, Mr. Pien served on the boards of ViroPharma, where he was also the Lead Independent Director, Vanda Pharmaceuticals, Inc., and Ikaria, Inc. In addition to board services, Mr. Pien is an advisor to Warburg Pincus, a private equity firm. Prior to board services, Mr Pien served as the CEO and Chairman of Medarex, Inc., a biopharmaceutical company, from June 2007 until it was acquired by BMS in September 2009. Mr. Pien served as the CEO and Chairman of Chiron Corporation, a biotechnology company, from April 2003 until its acquisition by Novartis in 2006. Prior to joining the biotechnology industry, Howard worked for GSK, Abbott Laboratories, and Merck & Co., Inc. Mr. Pien received a B.S. from MIT in 1979 and an M.B.A. from Carnegie-Mellon University in 1981.